Celularity Inc. heads into early May with its stock down sharply and a rare burst of options activity arriving against a backdrop where short sellers have largely stepped back.
The price tells the most immediate story. CELU closed at $0.957 on May 1 — down 14% on the week and 28% over the past month. A 2.4% bounce on the final session barely dents that run lower. The RSI14 has dropped to roughly 30, a level historically associated with heavily oversold conditions in small-cap biotech names. The stock's market cap is now around $27 million, deep in micro-cap territory.
The most striking development this week is in options. The put/call ratio has jumped to 0.052, which sounds low in absolute terms — but it is more than two standard deviations above its 20-day average of 0.020. For a stock that has traded with almost no put activity for months, that's a notable shift in hedging behaviour. The PCR 52-week high is 0.508, so this is far from extreme in absolute terms, but the directional change is sharp. Something prompted a fresh demand for downside protection just as the stock hit its monthly lows.
Short interest itself tells a less dramatic story. Estimated short interest runs at less than 1% of the free float — too thin to be a primary driver of either price pressure or a squeeze. Shorts did rebuild about 5% over the week in share terms, but they shed roughly 13% in a single session on April 30. Borrow costs have eased to around 5.97% — down 10% over the week and 16% over the past month, continuing a steady drift lower from the 7%-plus levels seen in late March. Availability remains wide. The lending market is not tight. The ORTEX short score of 41.7 is mid-range and has slipped from its weekly peak of 44.3 reached on April 27, reinforcing that the bears are not pressing hard here.
The ownership picture is concentrated and relatively illiquid. Genting Berhad holds nearly 18% of shares, with founder and CEO Robert Hariri controlling another 10%. The most recent insider activity on April 13 consisted of small equity awards and token sell transactions — the CEO offloaded 1,182 shares for roughly $1,500, and the Chief Administration Officer sold 583 shares for under $750. All trades were classified as low significance, and net insider value over 90 days amounts to just $2,600. This is not a signal either way; it reflects a stock so small that routine tax-cover sales look like noise.
There is a confirmed earnings event in the data — an announcement on April 30 — with a next-day price move of -0.3%. The prior release in April 2026 saw a -2.3% one-day reaction, while a November 2025 event produced a sharp 12% gain followed by 24% over five days. The variability in post-announcement behaviour is wide, consistent with a micro-cap name where low liquidity amplifies moves in either direction. Peer SNTI bounced 10% on Friday while KALA fell 20% on the week, illustrating how dispersed outcomes are across small-cap biotech right now.
The setup to watch is whether the options PCR stays elevated — or reverts — as the stock tests the sub-$1 level that has historically drawn attention in micro-cap names with institutional anchor holders still sitting on sizeable positions.
See the live data behind this article on ORTEX.
Open CELU on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
